Table 7.
Comparative chart of clinical and economic results for treatment of patients with hepatitis C genotype 1
| Therapeutic schedule | Total costs | LY1 | QALY2 | Result |
|---|---|---|---|---|
| Peginterferon-alfa-2a + ribavirin |
$Brz 31,185 |
14.51 |
12.89 |
peginterferon-alfa-2a is dominant |
| Peginterferon-alfa-2b + ribavirin | $Brz 39,186 | 14.35 | 12.50 |
Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.